Study of BGB-26808 alone or with tislelizumab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer that has spread or cannot be removed by surgery.
- You must have tried at least one standard treatment before, or standard treatment is not available or suitable for you.
- You must not have had treatment with certain immunotherapy drugs (like PD-1 or PD-L1 inhibitors) before.
- You must have a tumor sample (from a previous biopsy) that can be provided for testing.
- You must be well enough to carry out light activities (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
This study tests a new drug called BG-C0979 for advanced solid tumors that have not responded to standard treatments. It may be given alone or with other therapies to see if it can shrink tumors or slow cancer growth.
This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.
This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.
This trial tests a new treatment, BG-T187, given alone or with other medicines for people with advanced solid tumors that have spread or cannot be removed. It is for those who have already tried other treatments.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.